Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Dr. Sharon Klier, an executive leader with extensive experience in clinical development across early and late-stage programs, regulatory submissions, and approvals, to the role of Chief Development Officer. In this key role, Dr. Klier will oversee and provide strategic leadership across the clinical development and operations of Oculis’ robust ophthalmology pipeline.
Dr. Klier has over 20 years’ experience developing and executing global clinical development strategies that have supported product approvals and successful launches in retina and corneal diseases. Before joining Oculis, she served as Chief Development Officer, Head of Ophthalmology at UNITY Biotechnology, where she played a key role in driving forward UNITY’s pipeline. Prior to that, Dr. Klier held roles of increasing responsibility at several companies including Quark, Allergan, ISTA and Pfizer, where she gained extensive experience in ophthalmology, particularly in retinal diseases, neuro-ophthalmology, and ocular inflammation.
Riad Sherif, M.D., Chief Executive Officer of Oculis: “We are delighted that Sharon is joining Oculis’ strong R&D team. Sharon’s breadth of knowledge in ophthalmology, alongside her expertise in drug development, will be crucial as we continue to progress our late-stage pipeline. Her leadership experience, along with her proven track record in taking programs from late discovery through regulatory approval, will be instrumental as we continue to successfully execute our strategic vision.”
Sharon Klier, M.D., M.S., M.P.H., Chief Development Officer of Oculis: “I am excited to join the Oculis team, and have been so impressed by the company’s innovative, diverse and successful pipeline. I look forward to applying my expertise in clinical development across the different clinical programs, and to working with this skilled and accomplished team to make significant strides towards delivering new and transformative therapies for eye diseases.”
Should you invest $2,000 in OCS right now?
Before you buy stock in OCS, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is OCS one of them?
Reveal Undervalued Stocks Now